Advertisement
New Zealand markets close in 5 hours 27 minutes
  • NZX 50

    11,715.05
    -29.34 (-0.25%)
     
  • NZD/USD

    0.6111
    +0.0023 (+0.38%)
     
  • ALL ORDS

    8,007.10
    +47.60 (+0.60%)
     
  • OIL

    79.81
    -0.16 (-0.20%)
     
  • GOLD

    2,091.60
    -4.10 (-0.20%)
     

Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?

Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?

On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not be advancing into late-stage clinical trials. Now, the company's bid to capture portions of the extremely lucrative type 2 diabetes and obesity drug markets looks like it's in trouble.